FDA issues draft guidance for approving personalized gene-editing therapies for rare diseases

The guidance centers on what the agency calls an Individualized Feature Space, a set of predefined limits on how a product may vary from patient to patient while staying within a single Biologics License Application. A new patient-specific version that falls inside those limits can be added after approval without new clinical trials, relying on the trials behind the original approval plus laboratory data showing adequate safety and activity, HHS said.

The document also covers manufacturing, testing for unintended genetic changes, and naming and labeling. The FDA is taking public comments for 30 days after publication in the Federal Register, which printed the notice on Wednesday. Separately, CMS said it will widen its Cell and Gene Therapy Access Model beyond sickle cell disease and invite manufacturers of therapies for other conditions to apply.

Why it matters: Some rare diseases are caused by mutations that differ from patient to patient, so a single fixed product cannot treat everyone with the condition, and developers had sought clarity on how such therapies could be approved.